Compounds | Isozymes | Inhibition type | Ki (μM) | α | R2 | AICs | SCs | Selection | Cmax/Ki |
---|---|---|---|---|---|---|---|---|---|
Astragaloside IV (B2) | CYP2C9 | Competitive | 17.4 ± 3.7 | – | 0.9480 | − 113.3 | − 110.3 | ||
Noncompetitive | 55.8 ± 5.3 | – | 0.9708 | − 124.8 | − 121.8 | √ | 0.04 | ||
Mixed-type | 45.0 ± 16.6 | 1.5 ± 1.0 | 0.9713 | − 123.1 | − 119.2 | ||||
Ginsenoside Rg1 (C6) | UGT1A1 | Competitive | 140.6 ± 10.5 | – | 0.9952 | 176.4 | 179.4 | √ | 0.01 |
Noncompetitive | 187.2 ± 12.7 | – | 0.9943 | 179.8 | 182.8 | ||||
Mixed-type | 147.3 ± 29.9 | 8.3 ± 37.2 | 0.9952 | 178.7 | 182.7 | ||||
Ginsenoside Re (C9) | CYP2C8 | Competitive | 8.2 ± 1.1 | – | 0.9790 | − 121.3 | − 118.3 | ||
Noncompetitive | 26.5 ± 2.2 | – | 0.9793 | − 121.6 | − 118.6 | ||||
Mixed-type | 13.3 ± 2.9 | 4.2 ± 2.3 | 0.9862 | − 127.8 | − 123.8 | √ | 0.1 | ||
Ginsenoside Rd (D2) | CYP2B6 | Competitive | 10.2 ± 2.1 | – | 0.9484 | 19.4 | 22.4 | ||
Noncompetitive | 37.2 ± 2.3 | – | 0.9877 | − 9.2 | − 6.2 | √ | 0.02 | ||
Mixed-type | 36.3 ± 10.2 | 1.0 ± 0.4 | 0.9877 | − 7.2 | − 3.2 | ||||
Ginsenoside Rd (D2) | CYP3A4 | Competitive | 8.7 ± 2.3 | – | 0.9226 | − 31.9 | − 28.9 | ||
Noncompetitive | 32.8 ± 2.2 | – | 0.9846 | − 64.2 | − 61.2 | √ | 0.02 | ||
Mixed-type | 44.2 ± 16.2 | 0.6 ± 0.3 | 0.9854 | − 63.3 | − 59.3 | ||||
Ginsenoside Rc (D3) | UGT1A9 | Competitive | 8.9 ± 1.5 | – | 0.9634 | 122.8 | 125.8 | ||
Noncompetitive | 22.3 ± 1.4 | – | 0.9877 | 100.9 | 103.9 | √ | 0.04 | ||
Mixed-type | 27.0 ± 7.5 | 0.7 ± 0.3 | 0.9881 | 102.3 | 106.3 | ||||
Ginsenoside Rb1 (D5) | CYP2C9 | Competitive | 8.2 ± 1.0 | – | 0.9812 | − 115.9 | − 112.9 | ||
Noncompetitive | 16.1 ± 0.9 | – | 0.9921 | − 133.2 | − 130.3 | √ | 0.03 | ||
Mixed-type | 18.8 ± 4.3 | 0.7 ± 0.3 | 0.9923 | − 131.8 | − 127.9 |